[Methods and Principles in Medicinal Chemistry] Predictive Toxicology || Immunogenicity of Protein Therapeutics: Risk Assessment and Risk Mitigation

[Methods and Principles in Medicinal Che

[Methods and Principles in Medicinal Chemistry] Predictive Toxicology || Role of Modeling and Simulation in Toxicology Prediction

✍ Pfannkuch, Friedlieb; Suter-Dick, Laura 📂 Article 📅 2014 🏛 Wiley-VCH Verlag GmbH & Co. KGaA 🌐 German ⚖ 289 KB

[Methods and Principles in Medicinal Che

[Methods and Principles in Medicinal Chemistry] Predictive Toxicology || Discovery and Application of Novel Biomarkers

✍ Pfannkuch, Friedlieb; Suter-Dick, Laura 📂 Article 📅 2014 🏛 Wiley-VCH Verlag GmbH & Co. KGaA 🌐 German ⚖ 239 KB

[Methods and Principles in Medicinal Che

[Methods and Principles in Medicinal Chemistry] Hit and Lead Profiling Volume 43 || Integrative Risk Assessment

✍ Faller, Bernard; Urban, Laszlo 📂 Article 📅 2009 🏛 Wiley 🌐 German ⚖ 242 KB

The enormous cost incurred when a candidate drug fails in a clinical trial because of poor pharmacological parameters or severe side effects makes it imperative to screen for "safe" drugs in the very early stages of drug development. Various biochemical and other in vitro assays are thus used in con

[Methods and Principles in Medicinal Che

[Methods and Principles in Medicinal Chemistry] Predictive Toxicology || Genomic Applications for Assessing Toxicities of Liver and Kidney Injury

✍ Pfannkuch, Friedlieb; Suter-Dick, Laura 📂 Article 📅 2014 🏛 Wiley-VCH Verlag GmbH & Co. KGaA 🌐 German ⚖ 244 KB

Meeting report on protein particles and

Meeting report on protein particles and immunogenicity of therapeutic proteins: Filling in the gaps in risk evaluation and mitigation

✍ John Carpenter; Barry Cherney; Anthony Lubinecki; Stacey Ma; Ewa Marszal; Anthon 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 170 KB

[Methods and Principles in Medicinal Che

[Methods and Principles in Medicinal Chemistry] Hit and Lead Profiling Volume 43 || Drug-Drug Interactions: Screening for Liability and Assessment of Risk

✍ Faller, Bernard; Urban, Laszlo 📂 Article 📅 2009 🏛 Wiley 🌐 German ⚖ 282 KB

The enormous cost incurred when a candidate drug fails in a clinical trial because of poor pharmacological parameters or severe side effects makes it imperative to screen for "safe" drugs in the very early stages of drug development. Various biochemical and other in vitro assays are thus used in con